287 related articles for article (PubMed ID: 22061047)
1. Evaluation of bioactive sphingolipids in 4-HPR-resistant leukemia cells.
Apraiz A; Idkowiak-Baldys JK; Boyano MD; Pérez-Yarza G; Hannun YA; Asumendi A
BMC Cancer; 2011 Nov; 11():477. PubMed ID: 22061047
[TBL] [Abstract][Full Text] [Related]
2. Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death.
Apraiz A; Idkowiak-Baldys J; Nieto-Rementería N; Boyano MD; Hannun YA; Asumendi A
Biochem Cell Biol; 2012 Apr; 90(2):209-23. PubMed ID: 22428532
[TBL] [Abstract][Full Text] [Related]
3. Altered sphingolipid metabolism in N-(4-hydroxyphenyl)-retinamide-resistant A2780 human ovarian carcinoma cells.
Prinetti A; Basso L; Appierto V; Villani MG; Valsecchi M; Loberto N; Prioni S; Chigorno V; Cavadini E; Formelli F; Sonnino S
J Biol Chem; 2003 Feb; 278(8):5574-83. PubMed ID: 12486134
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of ceramide generation and metabolism in response to fenretinide--Diversity within and among leukemia.
Morad SA; Davis TS; Kester M; Loughran TP; Cabot MC
Leuk Res; 2015 Oct; 39(10):1071-8. PubMed ID: 26220867
[TBL] [Abstract][Full Text] [Related]
5. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism.
Maurer BJ; Melton L; Billups C; Cabot MC; Reynolds CP
J Natl Cancer Inst; 2000 Dec; 92(23):1897-909. PubMed ID: 11106681
[TBL] [Abstract][Full Text] [Related]
6.
Hayashi Y; Tsuchiya K; Yamamoto M; Nemoto-Sasaki Y; Tanigawa K; Hama K; Ueda Y; Tanikawa T; Gohda J; Maeda K; Inoue JI; Yamashita A
J Virol; 2021 Aug; 95(17):e0080721. PubMed ID: 34106748
[TBL] [Abstract][Full Text] [Related]
7. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators.
Batra S; Reynolds CP; Maurer BJ
Cancer Res; 2004 Aug; 64(15):5415-24. PubMed ID: 15289350
[TBL] [Abstract][Full Text] [Related]
8. N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes.
O'Donnell PH; Guo WX; Reynolds CP; Maurer BJ
Leukemia; 2002 May; 16(5):902-10. PubMed ID: 11986953
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine kinase mediates resistance to the synthetic retinoid N-(4-hydroxyphenyl)retinamide in human ovarian cancer cells.
Illuzzi G; Bernacchioni C; Aureli M; Prioni S; Frera G; Donati C; Valsecchi M; Chigorno V; Bruni P; Sonnino S; Prinetti A
J Biol Chem; 2010 Jun; 285(24):18594-602. PubMed ID: 20404323
[TBL] [Abstract][Full Text] [Related]
10. N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase.
Wang H; Maurer BJ; Reynolds CP; Cabot MC
Cancer Res; 2001 Jul; 61(13):5102-5. PubMed ID: 11431347
[TBL] [Abstract][Full Text] [Related]
11. N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing.
Wang H; Maurer BJ; Liu YY; Wang E; Allegood JC; Kelly S; Symolon H; Liu Y; Merrill AH; Gouazé-Andersson V; Yu JY; Giuliano AE; Cabot MC
Mol Cancer Ther; 2008 Sep; 7(9):2967-76. PubMed ID: 18790777
[TBL] [Abstract][Full Text] [Related]
12. N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).
Faderl S; Lotan R; Kantarjian HM; Harris D; Van Q; Estrov Z
Leuk Res; 2003 Mar; 27(3):259-66. PubMed ID: 12537979
[TBL] [Abstract][Full Text] [Related]
13. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines.
Maurer BJ; Metelitsa LS; Seeger RC; Cabot MC; Reynolds CP
J Natl Cancer Inst; 1999 Jul; 91(13):1138-46. PubMed ID: 10393722
[TBL] [Abstract][Full Text] [Related]
14. Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.
Morad SA; Tan SF; Feith DJ; Kester M; Claxton DF; Loughran TP; Barth BM; Fox TE; Cabot MC
Biochim Biophys Acta; 2015 Jul; 1851(7):919-28. PubMed ID: 25769964
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
[TBL] [Abstract][Full Text] [Related]
16. Enhanced apoptotic cancer cell killing after Foscan photodynamic therapy combined with fenretinide via de novo sphingolipid biosynthesis pathway.
Boppana NB; DeLor JS; Van Buren E; Bielawska A; Bielawski J; Pierce JS; Korbelik M; Separovic D
J Photochem Photobiol B; 2016 Jun; 159():191-5. PubMed ID: 27085050
[TBL] [Abstract][Full Text] [Related]
17. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl)retinamide] sufficient for cancer therapy?
Ohlmann CH; Jung C; Jaques G
Int J Cancer; 2002 Aug; 100(5):520-6. PubMed ID: 12124800
[TBL] [Abstract][Full Text] [Related]
18. Identification of dihydroceramide desaturase as a direct in vitro target for fenretinide.
Rahmaniyan M; Curley RW; Obeid LM; Hannun YA; Kraveka JM
J Biol Chem; 2011 Jul; 286(28):24754-64. PubMed ID: 21543327
[TBL] [Abstract][Full Text] [Related]
19. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
[TBL] [Abstract][Full Text] [Related]
20. Fenretinide-induced caspase-8 activation and apoptosis in an established model of metastatic neuroblastoma.
Raguénez G; Mühlethaler-Mottet A; Meier R; Duros C; Bénard J; Gross N
BMC Cancer; 2009 Mar; 9():97. PubMed ID: 19331667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
